The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies

References

• OlyaeiAJStefflJLA quantitative approach to drug dosing in chronic kidney diseaseBlood Purif2011311–313814521228582
   PubMed Web of Science ®Google Scholar
• OjoAAddressing the global burden of chronic kidney disease through clinical and translational researchTrans Am Clin Climatol Assoc2014125229243 discussion 243–24625125737
   PubMedGoogle Scholar
• TedlaFMBrarABrowneRBrownCHypertension in chronic kidney disease: navigating the evidenceInt J Hypertens2011201113240521747971
   PubMedGoogle Scholar
• Olechnowicz-TietzSGlubaAParadowskaABanachMRyszJThe risk of atherosclerosis in patients with chronic kidney diseaseInt Urol Nephrol20134561605161223483304
   PubMed Web of Science ®Google Scholar
• TuttleKRBakrisGLBilousRWDiabetic kidney disease: a report from an ADA Consensus ConferenceDiabetes Care201437102864288325249672
   PubMed Web of Science ®Google Scholar
• SavareseGDei CasARosanoGReduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trialsInt J Cardiol2014172240341024502877
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work GroupKDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney diseaseKidney Int Suppl2013311163
   Web of Science ®Google Scholar
• PlantingaLCCrewsDCCoreshJPrevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetesClin J Am Soc Nephrol20105467368220338960
   PubMed Web of Science ®Google Scholar
• Hippisley-CoxJCouplandCPredicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney ScoresBMC Fam Pract2010114920565929
   PubMed Web of Science ®Google Scholar
• FowlerMJMicrovascular complications of diabetesClin Diabetes20082627782
   Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas7th ednBrussels, BelgiumInternational Diabetes Federation2015
   Google Scholar
• LyssenkoVLaaksoMGenetic screening for the risk of type 2 diabetes: worthless or valuable?Diabetes Care201336Suppl 2S120S12623882036
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• PerkovicVHeerspinkHLChalmersJIntensive glucose control improves kidney outcomes in patients with type 2 diabetesKidney Int201383351752323302714
   PubMed Web of Science ®Google Scholar
• GaedePVedelPLarsenNJensenGVParvingHHPedersenOMultifactorial intervention and cardiovascular disease in patients with type 2 diabetesN Engl J Med2003348538339312556541
   PubMed Web of Science ®Google Scholar
• McIntoshBCameronCSinghSRSecond-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysisOpen Med201151e35e4822046219
   PubMedGoogle Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care201538114014925538310
   PubMed Web of Science ®Google Scholar
• YaleJFOral antihyperglycemic agents and renal disease: new agents, new conceptsJ Am Soc Nephrol200516Suppl 1S7S1015938025
   PubMed Web of Science ®Google Scholar
• CavanaughKDiabetes management issues for patients with chronic kidney diseaseClin Diabetes20072539097
   Google Scholar
• TakedaActos (pioglitazone) Summary of Product Characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/4236Accessed November 2015
   Google Scholar
• Merck SeronoGlucophage (metformin) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/1043Accessed November 2015
   Google Scholar
• Pfizer LimitedMinodiab (glipizide) Summary of Product Characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/9851Accessed November 2015
   Google Scholar
• Wockhardt UK LimitedGlibenclamide Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/30411Accessed November 2015
   Google Scholar
• Wockhardt UK LimitedGliclazide Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/27762Accessed November 2015
   Google Scholar
• Accord Healthcare LimitedGlimepiride Summary of Product Characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/25813Accessed November 2015
   Google Scholar
• Novo Nordisk LimitedPrandin (repaglinide) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/18980Accessed November 2015
   Google Scholar
• Eli Lilly and Company LimitedHumulin I (isophane insulin) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/3425Accessed November 2015
   Google Scholar
• Sanofi-aventisLantus (insulin glargine) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/25506Accessed November 2015
   Google Scholar
• Novo Nordisk LimitedLevemir (insulin detemir) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/14584Accessed November 2015
   Google Scholar
• Novo Nordisk LimitedTresiba (insulin degludec) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/27360Accessed November 2015
   Google Scholar
• Eli Lilly and Company LimitedHumalog (insulin lispro) Summary of Product Characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/30005Accessed November 2015
   Google Scholar
• SanofiApidra (insulin glulisine) Summary of Product Characteristics2013 Available from: https://www.medicines.org.uk/emc/medicine/26476Accessed November 2015
   Google Scholar
• Novo Nordisk LimitedNovoMix (insulin aspart) Summary of Product Characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/8591Accessed November 2015
   Google Scholar
• Actavis UK LtdAcarbose Summary of Product Characteristics2013 Available from: https://www.medicines.org.uk/emc/medicine/27829Accessed February 2016
   Google Scholar
• BrownJBPedulaKBarzilayJHersonMKLatarePLactic acidosis rates in type 2 diabetesDiabetes Care19982110165916639773726
   PubMed Web of Science ®Google Scholar
• RojasLBGomesMBMetformin: an old but still the best treatment for type 2 diabetesDiabetol Metab Syndr201351623415113
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE)The management of type 2 diabetes (CG87)LondonNational Institute for Clinical Excellence [Published May 2009]. Available from: http://guidance.nice.org.uk/cg87Accessed June 16, 2015
   Google Scholar
• InzucchiSELipskaKJMayoHBaileyCJMcGuireDKMetformin in patients with type 2 diabetes and kidney disease: a systematic reviewJAMA2014312242668267525536258
   PubMed Web of Science ®Google Scholar
• National Kidney FoundationKDOQI clinical practice guideline for diabetes and CKD: 2012 updateAm J Kidney Dis201260585088623067652
   PubMed Web of Science ®Google Scholar
• KasliwalRWiltonLVShakirSAMonitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in EnglandDrug Saf2008311083985018759508
   PubMed Web of Science ®Google Scholar
• ShayaFTLuZSohnKWeirMRThiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agentsP T200934949050120140111
   PubMedGoogle Scholar
• RosakCMertesGCritical evaluation of the role of acarbose in the treatment of diabetes: patient considerationsDiabetes Metab Syndr Obes2012535736723093911
   PubMedGoogle Scholar
• AstraZenecaABSymlin (pramlintide acetate) Prescribing Information2014 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021332s025lbl.pdfAccessed February 2016
   Google Scholar
• DefronzoRABromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetesDiabetes Care201134478979421447659
   PubMed Web of Science ®Google Scholar
• VeroScienceCycloset (bromocriptine) Prescribing Information2016 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdfAccessed February 2016
   Google Scholar
• SanofiToujeo (insulin glargine) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/30586Accessed November 2015
   Google Scholar
• SimpsonDMcCormackPLKeatingGMLyseng-WilliamsonKAInsulin lispro: a review of its use in the management of diabetes mellitusDrugs200767340743417335298
   PubMed Web of Science ®Google Scholar
• DreyerMPragerRRobinsonAEfficacy and safety of insulin glulisine in patients with type 1 diabetesHorm Metab Res2005371170270716308840
   PubMed Web of Science ®Google Scholar
• OwensDVoraJInsulin aspart: a reviewExpert Opin Drug Metab Toxicol20062579380417014395
   PubMed Web of Science ®Google Scholar
• DuckworthWCBennettRGHamelFGInsulin degradation: progress and potentialEndocr Rev19981956086249793760
   PubMed Web of Science ®Google Scholar
• GoykhmanSDrincicADesmanglesJCRendellMInsulin glargine: a review 8 years after its introductionExpert Opin Pharmacother200910470571819284367
   PubMed Web of Science ®Google Scholar
• IglesiasPDiezJJInsulin therapy in renal diseaseDiabetes Obes Metab2008101081182318248491
   PubMed Web of Science ®Google Scholar
• JacobsenLPopescuGPlumAPharmacokinetics of insulin detemir in subjects with renal or hepatic impairmentDiabetologia200245A259A260
   Web of Science ®Google Scholar
• KissIAroldGRoepstorffCBottcherSGKlimSHaahrHInsulin degludec: pharmacokinetics in patients with renal impairmentClin Pharmacokinet201453217518324163264
   PubMed Web of Science ®Google Scholar
• HolmesGGalitzLHuPLynessWPharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairmentBr J Clin Pharmacol200560546947616236036
   PubMed Web of Science ®Google Scholar
• Merck Sharp and Dohme LimitedJanuvia (sitagliptin) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/19609Accessed November 2015
   Google Scholar
• Novartis Pharmaceuticals UK LtdGalvus (vildagliptin) Summary of Product Characteristics2016 Available from: https://www.medicines.org.uk/emc/medicine/20734Accessed January 2016
   Google Scholar
• AstraZeneca UK LimitedOnglyza (saxagliptin) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/22315Accessed February 2016
   Google Scholar
• Boehringer Ingelheim LimitedTrajenta (linagliptin) Summary of Product Characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/25000Accessed November 2015
   Google Scholar
• Takeda UK LtdVipidia (alogliptin) Summary of product characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/28513Accessed November 2015
   Google Scholar
• AstraZeneca UK LimitedByetta (exenatide) Summary of Product Characteristics2016 Available from: https://www.medicines.org.uk/emc/medicine/19257Accessed January 2016
   Google Scholar
• AstraZeneca UK LimitedBydureon (exenatide) Summary of Product Characteristics2016 Available from: https://www.medicines.org.uk/emc/medicine/24665Accessed February 2016
   Google Scholar
• Sanofi-aventisLyxumia (lixisenatide) Summary of Product Characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/27405Accessed November 2015
   Google Scholar
• Novo Nordisk LimitedVictoza (liraglutide) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/21986Accessed November 2015
   Google Scholar
• GlaxoSmithKline Trading Services LimitedEperzan (albiglutide) Summary of Product Characteristics2016 Available from: https://www.medicines.org.uk/emc/medicine/31399Accessed February 2016
   Google Scholar
• Eli Lilly and Company LimitedTrulicity (dulaglutide) Summary of Product Characteristics2016 Available from: https://www.medicines.org.uk/emc/medicine/29747Accessed February 2016
   Google Scholar
• AstraZeneca UK LimitedForxiga (dapagliflozin) Summary of Product Characteristics2014 Available from: https://www.medicines.org.uk/emc/medicine/27188Accessed November 2015
   Google Scholar
• Janssen-Cilag LtdInvokana (canagliflozin) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/28400Accessed February 2016
   Google Scholar
• Boehringer Ingelheim LimitedJardiance (empagliflozin) Summary of Product Characteristics2015 Available from: https://www.medicines.org.uk/emc/medicine/28973Accessed November 2015
   Google Scholar
• MuskietMHSmitsMMMorsinkLMDiamantMThe gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Nat Rev Nephrol20141028810324375052
   PubMed Web of Science ®Google Scholar
• ChengDFeiYLiuYEfficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysisPLoS One2014910e11154325360775
   PubMed Web of Science ®Google Scholar
• GameFNovel hypoglycaemic agents: considerations in patients with chronic kidney diseaseNephron Clin Pract20141261141824434725
   PubMedGoogle Scholar
• AmoriRELauJPittasAGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJAMA2007298219420617622601
   PubMed Web of Science ®Google Scholar
• TriccoACAntonyJKhanPASafety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysisBMJ Open2014412e005752
   Web of Science ®Google Scholar
• BrownNJByiersSCarrDMaldonadoMWarnerBADipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedemaHypertension200954351652319581505
   PubMed Web of Science ®Google Scholar
• DeaconCFDipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative reviewDiabetes Obes Metab201113171821114598
   PubMed Web of Science ®Google Scholar
• BergmanAJCoteJYiBEffect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitorDiabetes Care20073071862186417468348
   PubMed Web of Science ®Google Scholar
• HeYLFlanneryBWangYThe influence of renal impairment on pharmacokinetics of vildagliptin (Abstract PIII-86)Clin Pharmacol Ther200781Suppl 1S113
   Google Scholar
• HeYLKulmatyckiKZhangYPharmacokinetics of vildagliptin in patients with varying degrees of renal impairmentInt J Clin Pharmacol Ther201351969370323782585
   PubMed Web of Science ®Google Scholar
• BoultonDWLiLFrevertEUInfluence of renal or hepatic impairment on the pharmacokinetics of saxagliptinClin Pharmacokinet201150425326521348538
   PubMed Web of Science ®Google Scholar
• Graefe-ModyUFriedrichCPortAEffect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)Diabetes Obes Metab2011131093994621672124
   PubMed Web of Science ®Google Scholar
• KarimAFleckPHetmanLSingle-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment (Abstract 538-P)Diabetes200857Suppl 1A160
   Google Scholar
• GreenJBBethelMAArmstrongPWEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med2015373323224226052984
   PubMed Web of Science ®Google Scholar
• MoriHOkadaYAraoTTanakaYSitagliptin improves albuminuria in patients with type 2 diabetes mellitusJ Diabetes Investig201453313319
   PubMed Web of Science ®Google Scholar
• HeHTranPYinHAbsorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humansDrug Metab Dispos200937353654419074975
   PubMed Web of Science ®Google Scholar
• WatanabeMFuruyaFKobayashiTDPP-4 inhibitor vildagliptin reduces urinary albumin excretion in type 2 diabetic patients with microalbuminuriaEndocrine Abstracts201229P687
   Google Scholar
• UdellJABhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 TrialDiabetes Care201538469670525552421
   PubMed Web of Science ®Google Scholar
• GroopPHCooperMEPerkovicVEmserAWoerleHJvon EynattenMLinagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunctionDiabetes Care201336113460346824026560
   PubMed Web of Science ®Google Scholar
• DineenLLawCScherRPyonEAlogliptin (nesina) for adults with type-2 diabetesP T201439318620224790396
   PubMedGoogle Scholar
• SakataKHayakawaMYanoYEfficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetesDiabetes Metab Res Rev201329862463023861159
   PubMed Web of Science ®Google Scholar
• AhrenBThe future of incretin-based therapy: novel avenues – novel targetsDiabetes Obes Metab201113Suppl 115816621824270
   PubMed Web of Science ®Google Scholar
• KuritzkyLUmpierrezGEkoeJMMancillas-AdameLLandoLFSafety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetesPostgrad Med20141266607225414935
   PubMed Web of Science ®Google Scholar
• TrujilloJMNufferWEllisSLGLP-1 receptor agonists: a review of head-to-head clinical studiesTher Adv Endocrinol Metab201561192825678953
   PubMed Web of Science ®Google Scholar
• LiLShenJBalaMMIncretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesBMJ2014348g236624736555
   PubMed Web of Science ®Google Scholar
• MeierJJGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNat Rev Endocrinol201281272874222945360
   PubMed Web of Science ®Google Scholar
• ZhangHZhangXHuCLuWExenatide reduces urinary transforming growth factor-beta1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuriaKidney Blood Press Res201235648348822687869
   PubMed Web of Science ®Google Scholar
• ImamuraSHiraiKHiraiAThe glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patientsTohoku J Exp Med20132311576124064677
   PubMed Web of Science ®Google Scholar
• LinnebjergHKotharePAParkSEffect of renal impairment on the pharmacokinetics of exenatideBr J Clin Pharmacol200764331732717425627
   PubMed Web of Science ®Google Scholar
• LiuYRuusPPharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment (abstract)Diabetes200959A149A150
   Google Scholar
• JacobsenLVHindsbergerCRobsonRZdravkovicMEffect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutideBr J Clin Pharmacol200968689890520002084
   PubMed Web of Science ®Google Scholar
• LoghinCde la PeñaACuiXZhangXGeiserJSChienJYPharmacokinetics of once weekly dulaglutide in special populationsDiabetologia201457Suppl 1S349
   Google Scholar
• YoungMAWaldJAMatthewsJEYangFReinhardtRREffect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutidePostgrad Med20141263354624918790
   PubMed Web of Science ®Google Scholar
• GedulinBRNikoulinaSESmithPAExenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weightEndocrinology200514642069207615618356
   PubMed Web of Science ®Google Scholar
• BarnettAHLixisenatide: evidence for its potential use in the treatment of type 2 diabetesCore Evid20116677922022289
   PubMedGoogle Scholar
• ZavattaroMCaputoMSamaMTOne-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective studyEndocrine201550362062625572181
   PubMed Web of Science ®Google Scholar
• DaviesMJBainSCAtkinSLEfficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trialDiabetes Care201639222223026681713
   PubMed Web of Science ®Google Scholar
• GarberAJLong-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerabilityDiabetes Care201134Suppl 2S27928421525469
   PubMed Web of Science ®Google Scholar
• MatthewsJEStewartMWDe BoeverEHPharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetesJ Clin Endocrinol Metab200893124810481718812476
   PubMed Web of Science ®Google Scholar
• BaysHFrom victim to ally: the kidney as an emerging target for the treatment of diabetes mellitusCurr Med Res Opin200925367168119232040
   PubMed Web of Science ®Google Scholar
• ChaoECSGLT-2 inhibitors: A new mechanism for glycemic controlClin Diabetes201432141126246672
   PubMedGoogle Scholar
• FerranniniESoliniASGLT2 inhibition in diabetes mellitus: rationale and clinical prospectsNat Rev Endocrinol20128849550222310849
   PubMed Web of Science ®Google Scholar
• NauckMAUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetesDrug Des Devel Ther2014813351380
   PubMed Web of Science ®Google Scholar
• PetersALBuschurEOBuseJBCohanPDinerJCHirschIBEuglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibitionDiabetes Care20153891687169326078479
   PubMed Web of Science ®Google Scholar
• KasichayanulaSLiuXPe BenitoMThe influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitusBr J Clin Pharmacol201376343244423210765
   PubMed Web of Science ®Google Scholar
• SteinPBergJKMorrowLCanagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trialMetabolism201463101296130325110280
   PubMed Web of Science ®Google Scholar
• Sarnoski-BrocavichSHilasOCanagliflozin (Invokana), a novel oral agent for type-2 diabetesP T2013381165666624391386
   PubMedGoogle Scholar
• InagakiNKondoKYoshinariTPharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairmentClin Drug Investig20143410731742
   Web of Science ®Google Scholar
• MachaSMattheusMHalabiAPinnettiSWoerleHJBroedlUCPharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairmentDiabetes Obes Metab201416321522223859488
   PubMed Web of Science ®Google Scholar
• KomoroskiBVachharajaniNBoultonDDapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjectsClin Pharmacol Ther200985552052619129748
   PubMed Web of Science ®Google Scholar
• NealBPerkovicVde ZeeuwDEfficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetesDiabetes Care201538340341125468945
   PubMed Web of Science ®Google Scholar
• InagakiNKondoKYoshinariTPharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairmentClin Drug Investig20143410731742
   Web of Science ®Google Scholar
• KohanDEFiorettoPTangWListJFLong-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic controlKidney Int201485496297124067431
   PubMed Web of Science ®Google Scholar
• BarnettAHMithalAManassieJEMPA-REG Renal Trial investigatorsEfficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trialLancet Diabetes Endocrinol20142536938424795251
   PubMed Web of Science ®Google Scholar
• YaleJFBakrisGCariouBEfficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes Obes Metab201315546347323464594
   PubMed Web of Science ®Google Scholar
• VallonVThe mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitusAnnu Rev Med20156625527025341005
   PubMed Web of Science ®Google Scholar
• University College DublinThe differential effects of diabetes therapy on inflammation Available from: https://clinicaltrials.gov/ct2/show/NCT02150707?term=NCT02150707&rank=1 NLM identifier: NCT02150707Accessed September 30, 2015
   Google Scholar
• Boehringer IngelheimCardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) Available from: https://clinicaltrials.gov/ct2/show/NCT01897532?term=NCT01897532&rank=1. NLM identifier: NCT01897532Accessed September 30, 2015
   Google Scholar
• Boehringer IngelheimMARLINA – T2D : Efficacy, Safety and Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin Available from: https://clinicaltrials.gov/ct2/show/record/NCT01792518. NLM identifier: NCT01792518Accessed November 30, 2015
   Google Scholar
• VU University Medical CenterRenal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes (RENALIS) Available from: https://clinicaltrials.gov/ct2/show/NCT02106104?term=NCT02106104&rank=1. NLM identifier: NCT02106104Accessed November 30, 2015
   Google Scholar
• Profil Institut für Stoffwechselforschung GmbHEffects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment Available from: https://clinicaltrials.gov/ct2/show/NCT01903070?term=NCT01903070&rank=1. NLM identifier: NCT01903070Accessed November 30, 2015
   Google Scholar
• Bristol-Myers SquibbRisk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments Available from: https://clinicaltrials.gov/ct2/show/NCT01377935?term=Comparison+of+Risk+of+Hospitalization+for+Acute+Kidney+Injury+Between+Patients+With+Type+2+Diabetes+Initiating+Saxagliptin&rank=1. NLM identifier: NCT01377935Accessed November 30, 2015
   Google Scholar
• Baylor Research InstituteExtended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome Available from: https://clinicaltrials.gov/ct2/show/NCT02251431. NLM identifier: NCT02251431Accessed November 30, 2015
   Google Scholar
• VU University Medical CenterEffect of LIXIsenatide on the Renal System (ELIXIRS) Available from: https://clinicaltrials.gov/ct2/show/NCT02276196. NLM identifier: NCT02276196Accessed November 30, 2015
   Google Scholar
• NeffKarlUniversity College DublinThe Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease Available from: https://clinicaltrials.gov/ct2/show/NCT01847313?term=The+Effect+of+Glucagon-like-peptide+1+%28GLP-1%29+Receptor+Agonism+on+Diabetic+Kidney+Disease&rank=1. NLM identifier: NCT01847313Accessed November 30, 2015
   Google Scholar
• MadirajuAKErionDMRahimiYMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenaseNature2014510750654254624847880
   PubMed Web of Science ®Google Scholar
• AstraZenecaABStudy to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE) Available from: https://clinicaltrials.gov/ct2/show/NCT02413398?term=Study+to+Evaluate+the+Effect+of+Dapagliflozin+on+Blood+Glucose+Level+and+Renal+Safety+in+Patients+With+Type+2+Diabetes&rank=1. NLM identifier: NCT02413398Accessed November 30, 2015
   Google Scholar
• Janssen Research Development, LLCA Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R) Available from: https://clinicaltrials.gov/ct2/show/record/NCT01989754. NLM identifier: NCT01989754Accessed November 30, 2015
   Google Scholar
• Janssen Research Development, LLCEvaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) Available from: https://clinicaltrials.gov/ct2/show/NCT02065791?term=NCT02065791&rank=1. NLM identifier: NCT02065791Accessed November 30, 2015
   Google Scholar
• Boehringer IngelheimEffect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls Available from: https://clinicaltrials.gov/ct2/show/NCT01867307?term=Effect+of+Empagliflozin+Kinetics+on+Renal+Glucose+Reabsorption+in+Patients+With+Type+II+Diabetes+and+Healthy+Controls&rank=1. NLM identifier: NCT01867307Accessed November 30, 2015
   Google Scholar
• GroopPHDel PratoSTaskinenMRLinagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairmentDiabetes Obes Metab201416656056824612167
   PubMed Web of Science ®Google Scholar
• MeierJJNauckMAKranzDSecretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjectsDiabetes200453365466214988249
   PubMed Web of Science ®Google Scholar
• ClementiAVirziGMGohCYCardiorenal syndrome type 4: a reviewCardiorenal Med201331637023946725
   PubMed Web of Science ®Google Scholar